Gene Solutions Expands SPOT-MAS Portfolio with Accessible Cancer Screening and Precision Triage Solutions
April 20, 2026 — Gene Solutions announced the expansion of its SPOT‑MAS portfolio with two new solutions: SPOT-MAS CRC and SPOT-MAS Eva. These additions bring accessible blood-based colorectal cancer screening and molecular precision triage for cervical and endometrial cancers.
Building on its leadership in cell-free DNA, cancer epigenetics, and AI-powered multi-omics, Gene Solutions continues to advance earlier and more precise cancer detection by matching the optimal technology to the clinical need – from accessible single-cancer screening to targeted triage and frontier multi-cancer early detection.
SPOT‑MAS CRC is a convenient, blood-based screening test that detects methylation changes in the SEPTIN9 gene from a single blood draw. It requires no bowel preparation or stool sampling and is positioned as an accessible option for colorectal cancer screening, in health-checkup settings where cost, convenience, and patient adherence matter. A 2024 prospective study published in BMC Cancer (Wu et al., n=1,366) reported 77.34% sensitivity for colorectal cancer detection, 95.95% specificity in non-CRC cases, and detection of 54.29% of high-grade intraepithelial neoplasia cases, highlighting the value of methylation-based blood testing as a minimally invasive alternative.
SPOT‑MAS Eva provides precision triage for the two most common gynecological cancers — cervical and endometrial cancer— in a single cervical swab workflow that integrates Cervix360 and epiHERA:
- HPV 28-type genotyping
- PAX1/JAM3 methylation
- CDO1/CELF4 methylation.
For cervical cancer triage in high-risk HPV-positive women, PAX1/JAM3 methylation (Liang Hui et al., Frontiers in Oncology 2024; n=436) achieved 92.6% sensitivity, 95.7% specificity, and an AUC of 0.941 for detecting CIN2+ lesions, while identifying all cervical cancer cases in the study cohort. The study concluded that PAX1/JAM3 methylation using cervical exfoliated cells showed superior triage performance compared with traditional strategies.
For endometrial cancer triage, epiHERA addresses a major unmet need in women presenting with abnormal uterine bleeding, suspicious imaging findings, or other clinical risk factors. In a 2025 prospective study published in Cancers (Lee et al., The Chinese University of Hong Kong, n=675), the CDO1/CELF4 methylation (epiHERA®) assay, performed on cervical scrapings, demonstrated 97.3% accuracy, 84.1% sensitivity, 98.8% specificity, 89.2% positive predictive value, 98.2% negative predictive value, and an AUC of 0.92 for endometrial cancer detection. The validation showed that the assay may serve as a triage tool to reduce invasive endometrial assessment.
The new additions strengthen the SPOT‑MAS portfolio by delivering the appropriate level of molecular insight for accessible screening and targeted triage, complementing our frontier multi-cancer early detection solution. By matching the right technology to the right clinical context, Gene Solutions is extending molecular precision beyond specialized settings and into everyday practice.
“Our identity has always been rooted in molecular precision and deep cancer biology insight, with established leadership in NGS and AI-powered multi-omics. By expanding the SPOT-MAS portfolio with accessible epigenetic solutions such as SPOT-MAS CRC and SPOT-MAS Eva, we extend that same precision to broader screening and targeted triage — bringing earlier detection and clearer decision-making to more patients.”– said Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions.
Gene Solutions believes the future of cancer diagnostics will be built on an integrated portfolio that delivers the right level of molecular precision for each clinical need. With SPOT‑MAS CRC and SPOT‑MAS Eva, the company is reinforcing its commitment to deliver earlier detection, clearer triage decisions, and broader access to clinically meaningful cancer testing – extending the benefits of molecular precision to more patients worldwide.
Learn more about the tests at:
About Gene Solutions:
Gene Solutions is a global biotechnology company headquartered in Singapore with a mission to make advanced genomic solutions accessible and affordable. Leveraging multi-omics, Next-Generation Sequencing (NGS), and Artificial Intelligence, the company offers a comprehensive portfolio, including next-generation prenatal screening for fetal and maternal health (triSure), multi-cancer early detection (SPOT-MAS), and comprehensive tumor profiling and ctDNA monitoring (K-TRACK, K-4CARE).
Since 2017, Gene Solutions has performed over three million genetic tests worldwide through CAP-accredited laboratories across multiple markets. Through continuous innovation and strategic collaborations, the company is advancing earlier cancer detection, precision care, and reproductive health globally. For more information, visit www.genesolutions.com and follow the company on LinkedIn and Facebook.
